Is TB-500 Better Than TB500? (Same Peptide, Different Names)

A supplier offers 'TB-500' at one price point, another lists 'TB500' at a different cost, and researchers wonder if they're comparing two distinct peptides. They're not. TB-500 and TB500 are naming conventions for the same synthetic peptide. A 43-amino-acid fragment of Thymosin Beta-4 (Tβ4). The hyphen and capitalization differences reflect branding choices, not molecular structure. The peptide's efficacy depends entirely on synthesis precision, purity level, and proper handling. Not whether the supplier added a hyphen.

We've guided hundreds of research teams through peptide sourcing decisions. The naming confusion wastes time that should be spent evaluating what actually determines research-grade quality: amino acid sequencing accuracy, sterility verification, and documentation of synthesis protocol.

Is TB-500 better than TB500?

TB-500 and TB500 refer to the same synthetic peptide. A 43-amino-acid fragment (residues 1–43) of Thymosin Beta-4. The naming variation exists because suppliers use different capitalization and hyphenation conventions, but the molecular structure remains identical when properly synthesized. Research quality depends on purity level (typically 98%+ for lab-grade peptides), synthesis method (solid-phase peptide synthesis being the standard), and third-party testing verification. Not the name format on the vial label.

The question 'is TB-500 better than TB500' assumes they're competing compounds. They're not. They're identical peptides sold under formatting variations. What researchers should evaluate instead: the supplier's synthesis protocol documentation, certificate of analysis availability, and whether the peptide was produced via small-batch or bulk synthesis. A poorly synthesized product labeled 'TB-500' with 92% purity underperforms a precisely manufactured 'TB500' at 99.5% purity every time. The name tells you nothing about the molecule inside the vial.

This article covers the molecular identity of both naming conventions, what purity and synthesis standards actually matter for research outcomes, and how to evaluate peptide quality when suppliers use different label formats.

The Molecular Identity: TB-500 and TB500 Are the Same Peptide Fragment

TB-500 and TB500 are both synthetic analogues of the naturally occurring peptide Thymosin Beta-4 (Tβ4), specifically comprising amino acids 1 through 43 of the full 43-residue sequence. The naming divergence stems from supplier branding preferences. Some use 'TB-500' with a hyphen and capitalized letters, others opt for 'TB500' as a single term. The amino acid sequence remains constant: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH. No structural variation exists between products labeled TB-500 and those labeled TB500 when synthesized to specification.

The peptide functions as a G-actin sequestering molecule, binding monomeric actin to prevent polymerization into filamentous structures. A mechanism relevant to cellular migration and tissue organization studies. Thymosin Beta-4 itself is a 43-amino-acid peptide first isolated from thymus tissue, and the synthetic fragment replicates the entire native sequence. The '500' suffix in both naming conventions refers to an early catalog designation, not a molecular weight or potency metric.

Suppliers differentiate through capitalization and hyphenation purely for trademark and search optimization purposes. A researcher ordering TB-500 from Real Peptides receives the same molecular entity as one ordering TB500 from any compliant supplier. Assuming both adhere to solid-phase peptide synthesis (SPPS) standards and achieve equivalent purity thresholds. The question of whether TB-500 is better than TB500 collapses when you examine the certificate of analysis: if both products list 98.5% purity via HPLC and identical mass spectrometry confirmation, they are functionally indistinguishable.

What Actually Determines Peptide Quality in Research Applications

Purity level is the first meaningful differentiator. Research-grade peptides typically achieve 95–99.5% purity via high-performance liquid chromatography (HPLC) analysis. A peptide synthesized at 92% purity contains 8% impurities. Truncated sequences, deletion peptides, or synthesis byproducts that can interfere with experimental results. For cell culture work, receptor binding studies, or in vivo models, a 5% impurity margin introduces enough variability to skew dose-response curves. Third-party HPLC verification confirms what percentage of the vial's contents matches the target sequence exactly.

Synthesis method determines sequence accuracy. Solid-phase peptide synthesis (SPPS) is the industry standard for producing peptides up to 50 amino acids, assembling the chain one residue at a time on a solid resin support. Small-batch SPPS allows tighter quality control than bulk automated synthesis. Each coupling reaction can be monitored and verified before proceeding to the next amino acid addition. Fmoc (9-fluorenylmethoxycarbonyl) chemistry is the dominant protection strategy, preventing unwanted side reactions during chain assembly. A supplier using outdated t-Boc chemistry or skipping intermediate purification steps produces peptides with higher deletion rates and lower overall purity.

Certificate of analysis (CoA) documentation separates compliant suppliers from those cutting corners. A legitimate CoA includes HPLC chromatogram data, mass spectrometry results confirming molecular weight, and peptide content quantification. It should also list endotoxin levels (typically <1 EU/mg for cell culture applications) and sterility verification if the product is marketed for biological use. Suppliers who provide only a purity percentage without supporting analytical data are asking researchers to trust claims that can't be independently verified. Our team evaluates peptide suppliers based on whether they make full CoA documentation available before purchase. Not just upon request after an issue arises.

Storage and handling post-synthesis affect peptide stability more than most researchers anticipate. Lyophilized (freeze-dried) peptides remain stable at −20°C for 12–24 months when stored in sealed vials with desiccant. Once reconstituted with bacteriostatic water or sterile saline, the peptide solution must be refrigerated at 2–8°C and used within 28 days. Longer storage periods allow oxidation of methionine residues and aggregation of hydrophobic sequences. A peptide shipped without cold chain protection or stored improperly after arrival degrades regardless of initial purity. The label format doesn't protect against temperature excursions during transit.

TB-500 Better Than TB500: Side-by-Side Comparison

Before evaluating supplier-specific differences, it's important to recognize that TB-500 and TB500 represent the same molecular entity under different naming conventions. The comparison below examines what factors actually differentiate one TB-500/TB500 product from another. Because the peptide's research utility depends on synthesis quality, not label formatting.

Key Takeaways

• TB-500 and TB500 are the same 43-amino-acid synthetic fragment of Thymosin Beta-4. The naming difference reflects supplier branding choices, not molecular variation.
• Purity level (verified via HPLC) and synthesis method (solid-phase peptide synthesis being the standard) determine research quality far more than whether a hyphen appears in the product name.
• A certificate of analysis with HPLC chromatogram data, mass spectrometry confirmation, and endotoxin testing is the only reliable way to verify that a peptide matches its claimed purity and sequence.
• Lyophilized peptides stored at −20°C remain stable for 12–24 months, but once reconstituted, the solution must be refrigerated at 2–8°C and used within 28 days to prevent oxidation and aggregation.
• Comparing 'TB-500 better than TB500' is functionally meaningless. Researchers should compare supplier quality control standards, synthesis documentation, and third-party testing rigor instead.

What If: TB-500 and TB500 Scenarios

What If I Order TB-500 From One Supplier and TB500 From Another — Will They Perform Differently in My Research?

The peptides will perform identically if both were synthesized to the same purity standard and stored properly. Compare the certificates of analysis for both products. If the HPLC purity, molecular weight via mass spectrometry, and peptide content percentage match, the naming convention is irrelevant. The only performance difference would stem from synthesis errors, impurity levels, or degradation during storage and shipping. If one supplier provides a 98.5% pure product and the other delivers 95%, the lower-purity peptide introduces more experimental variability. But that's a synthesis quality issue, not a TB-500 vs TB500 distinction.

What If a Supplier Lists 'TB-500' at a Higher Price Than 'TB500' — Does That Mean It's Higher Quality?

No. Pricing differences reflect supplier overhead, marketing strategy, and brand positioning, not molecular superiority. A supplier charging premium rates for 'TB-500' might invest more in quality control and third-party testing, or they might simply be marking up a commodity product. The only way to verify quality is by reviewing the certificate of analysis and synthesis documentation. We've seen suppliers charge 40% more for peptides with identical HPLC results to competitors. Price signals brand perception, not peptide purity.

What If I See Research Papers Citing 'TB-500' But Not 'TB500' — Should I Assume TB-500 Is the Standard Form?

Peer-reviewed literature uses whichever naming convention the supplier or research institution adopted, but the peptide being studied is the same. Some early publications used 'TB-500' because that was the catalog name from a specific supplier, and subsequent researchers cited that format for consistency. Others used 'TB500' or 'Thymosin Beta-4 fragment 1–43' interchangeably. The scientific community recognizes all three as referring to the same molecular entity. If you're replicating a study that used 'TB-500,' you can source 'TB500' from a different supplier as long as the purity and synthesis method match the original research protocol.

The Blunt Truth About TB-500 vs TB500

Here's the honest answer: asking whether TB-500 is better than TB500 is like asking whether H₂O is better than water. They're the same thing with different labels. The question exists because suppliers use different naming conventions and researchers assume the formatting must signify something meaningful. It doesn't. The amino acid sequence, molecular weight, and mechanism of action are identical when both peptides are synthesized correctly.

The real issue isn't hyphenation. It's that many researchers evaluate peptides based on supplier marketing instead of analytical verification. A vial labeled 'TB-500' from a supplier with no certificate of analysis, no HPLC documentation, and no third-party testing is objectively worse than a 'TB500' product from a facility that provides full synthesis records and sterility confirmation. The name on the label tells you nothing about what's inside the vial. The only meaningful comparison is between supplier quality control standards, not between naming formats.

When sourcing peptides for research, focus on purity percentage, synthesis method documentation, and whether the supplier provides mass spectrometry and HPLC verification before purchase. Those factors determine experimental reliability. The hyphen in 'TB-500' has no impact on actin-binding affinity, cellular uptake, or dose-response consistency. If two suppliers both deliver 99% pure Thymosin Beta-4 fragment 1–43, the one calling it 'TB-500' isn't better than the one calling it 'TB500'. They're equivalent products under different branding.

Why Supplier Quality Control Matters More Than Naming Conventions

The efficacy of TB-500 (or TB500, depending on your supplier's preference) in research applications depends entirely on whether the peptide was synthesized with accurate amino acid sequencing and minimal impurities. Solid-phase peptide synthesis allows for high precision, but only when each coupling step is verified before proceeding. Suppliers who rush synthesis or skip intermediate purification steps produce peptides with deletion sequences. Chains missing one or more amino acids. That can't replicate the intended biological function. A deletion peptide at 5% concentration in your vial means 5% of your experimental dose is inactive or potentially competitive at the target receptor.

Third-party testing separates compliant suppliers from those relying on in-house claims. A certificate of analysis issued by an independent laboratory confirms that the peptide purity, molecular weight, and sterility meet the stated specifications. Suppliers who conduct testing internally but refuse to share raw chromatogram data are asking researchers to trust results that can't be independently verified. Our experience working with research teams across multiple institutions shows that peptide-related experimental failures correlate strongly with suppliers who don't provide third-party CoA documentation upfront. The name format on the product page doesn't predict testing rigor. Supplier transparency does.

Small-batch synthesis offers tighter quality control than bulk production. Peptide synthesis at scale increases the risk of sequence errors, incomplete coupling reactions, and contamination from previous batches. Facilities that produce peptides in large volumes often prioritize throughput over verification, accepting slightly lower purity in exchange for faster production timelines. Small-batch synthesis allows each production run to be fully characterized before release, ensuring that every vial meets the target purity threshold. Researchers sourcing TB-500 or TB500 should ask suppliers about batch size and whether each batch undergoes individual HPLC analysis or whether testing occurs on representative samples only.

The TB-500 better than TB500 debate dissolves entirely when you evaluate suppliers on verifiable quality metrics. A supplier offering 'TB-500' at 97% purity with full mass spectrometry confirmation delivers a better research tool than one selling 'TB500' at 94% purity with no analytical documentation. And the reverse is equally true. The peptide's utility in actin sequestration studies, tissue repair models, or cell migration assays depends on molecular integrity, not marketing terminology.

Researchers working with peptides in demanding applications. Particularly those requiring precise dose-response curves or receptor binding specificity. Should prioritize suppliers who document synthesis method, provide batch-specific CoA data, and maintain cold chain integrity during shipping. Those are the factors that determine whether a peptide performs as expected in the lab. Whether the supplier hyphenates the name is irrelevant to experimental outcomes. When evaluating options, focus on what's verifiable: purity via HPLC, molecular weight via mass spectrometry, and sterility via endotoxin testing. The rest is branding.

If your research requires peptides synthesized with exact amino-acid sequencing and guaranteed purity, explore the full peptide collection at Real Peptides. Every product includes third-party verification and small-batch synthesis documentation.

The most reliable peptide isn't the one with the preferred name format. It's the one that arrives with a certificate of analysis proving it matches the claimed specification. That's the standard every research team should demand, regardless of whether the label reads TB-500 or TB500.